DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 74 · March 2020 DOI: 10.1055/s-010-46041


61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Leipzig, 25.–28.03.2020

Kongresspräsident: Prof. Dr. med. Gernot Rohde
Abstracts (HTML) Abstracts (PDF) List of Authors
P214
Schwarzkopf, L; Kotulla, R; Kreuter, M: Hospitalisierung im Kontext der Diagnose Interstitieller Lungenerkrankungen – Häufigkeit und Einflussfaktoren auf Basis bundesweiter Kassendaten
P317
van den Dool, W; Zenner, M; Ubl, B; Würth, H; Hetzel, K; Hetzel, M: Multidisziplinäre Fallbesprechung von Patienten mit diffusen parenchymatösen Lungenerkrankungen am RKK Stuttgart 2014 bis 2019
P312
Grohé, C; Schütte, W; Koerber, W; Seese, B; Koschel, D; Neuland, K; Schreiber, J: Non-interventional study AER plus: Clinical course of mild to moderate IPF during therapy with pirfenidone
P276
Piotraschke, L; Bigl, H; Vogler, M; Koschel, D: Klinische Erfahrungen mit antifibrotischer Therapie bei Patienten mit idiopathischer Lungenfibrose (IPF) unter besonderer Berücksichtigung des Therapiewechsels an einem tertiären Lungenzentrum
P166
Behr, J; Richeldi, L; Kolb, M; Jouneau, S; Wuyts, W; Tschoepe, I; Stowasser, S; Quaresma, M; Raghu, G: Consistent effect of nintedanib in patients with IPF and degrees of impairment in gas exchange*
P167
Bonella, F; Bendstrup, E; Bargagli, E; Stansen, W; Quaresma, M; Orsatti, L; Glaspole, I: Efficacy and safety of nintedanib in the elderly patient with IPF*
P168
Costabel, U; Crestani, B; Cottin, V; Thibault, R; Lederlin, M; Vernhet, L; Stansen, W; Quaresma, M; Jouneau, S: Association between weight loss and decline in FVC in patients with IPF*
P169
Gläser, S; Jouneau, S; Crestani, B; Thibault, R; Lederlin, M; Vernhet, L; Stansen, W; Quaresma, M; Cottin, V: Relationship between body mass index (BMI) and decline in FVC in patients with IPF*
P170
Koschel, D; Maher, TM; Cottin, V; Russell, AM; Corte, T; Hammerl, P; Michael, A; Rohr, KB; Quaresma, M; Stowasser, S; Noth, I: Correlation between home and clinic spirometry in subjects with IPF: results from the INMARK trial*
P171
Pfeifer, M; Maher, TM; Stowasser, S; Nishioka, Y; White, ES; Cottin, V; Noth, I; Selman, M; Rohr, KB; Wachtlin, D; Ittrich, C; Diefenbach, C; Jenkins, RG: Effect of nintedanib on biomarkers of extracellular matrix (ECM) turnover and FVC decline in patients with IPF: results from the INMARK study*
P172
Prasse, A; Maher, TM; Jenkins, RG; Cottin, V; Nishioka, Y; Noth, I; Selman, M; Song, JW; Ittrich, C; Diefenbach, C; Rohr, KB; Stowasser, S; White, ES: Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial*
P165
Behr, J; Kolb, M; Song, JW; Luppi, F; Schinzel, B; Stowasser, S; Quaresma, M; Martinez, FJ: Nintedanib plus sildenafil versus nintedanib alone in patients with IPF and severely impaired gas exchange: subgroup analysis by right heart dysfunction*
P164
Behr, J; Kolb, M; Olschewski, H; Song, JW; Luppi, F; Schinzel, B; Stowasser, S; Quaresma, M; Martinez, FJ: Does brain natriuretic peptide (BNP) at baseline influence the effects of nintedanib plus sildenafil in patients with IPF?
P160
Koschel, D; Flaherty, KR; Wells, AU; Cottin, V; Devaraj, A; Inoue, Y; Richeldi, L; Walsh, S; Stowasser, S; Coeck, C; Goeldner, RG; Clerisme-Beaty, E; Schlenker-Herceg, R; Brown, KK: Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial*